Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas

[1]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[2]  M. Nagane,et al.  Reduced H3K27me3 levels in diffuse gliomas: association with 1p/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors , 2020, Brain Tumor Pathology.

[3]  K. Rajmohan,et al.  Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas , 2020, Neurology India.

[4]  K. Aldape,et al.  cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors , 2020, Brain pathology.

[5]  Pieter Wesseling,et al.  cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading , 2020, Brain pathology.

[6]  D. Ellison.  Mini‐symposium in medulloblastoma genomics in the modern molecular era , 2020, Brain pathology.

[7]  G. Reifenberger,et al.  cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas , 2020, Acta Neuropathologica.

[8]  A. Natsume,et al.  Overview of DNA methylation in adult diffuse gliomas , 2019, Brain tumor pathology.

[9]  David T. W. Jones,et al.  cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation , 2019, Acta Neuropathologica.

[10]  Y. Sonoda,et al.  Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors , 2019, Brain Tumor Pathology.

[11]  G. Reifenberger,et al.  cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” , 2018, Acta Neuropathologica.

[12]  Pieter Wesseling,et al.  cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant , 2018, Acta Neuropathologica.

[13]  Hiromichi Suzuki,et al.  Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion , 2018, Brain Tumor Pathology.

[14]  D. Louis,et al.  cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC) , 2018, Acta Neuropathologica.

[15]  V. Santosh,et al.  A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up , 2017, Journal of Clinical Pathology.

[16]  Federica Grillo,et al.  Immunohistochemistry on old archival paraffin blocks: is there an expiry date? , 2017, Journal of Clinical Pathology.

[17]  Jennie W. Taylor,et al.  Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT , 2017, Acta Neuropathologica.

[18]  W. Paulus.  WHO 2016: Open questions and practical implications , 2017, Acta Neurochirurgica.

[19]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[20]  M. Noguchi,et al.  Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas , 2016, Brain Tumor Pathology.

[21]  M. Nerenberg,et al.  Loss of antigenicity with tissue age in breast cancer , 2016, Laboratory Investigation.

[22]  I. Vajtai,et al.  Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas , 2016, Histopathology.

[23]  Y. Kato,et al.  A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas. , 2015, Biochemical and biophysical research communications.

[24]  P. Decker,et al.  IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas , 2015, Oncotarget.

[25]  K. Ichimura,et al.  Revisiting TP53 Mutations and Immunohistochemistry—A Comparative Study in 157 Diffuse Gliomas , 2015, Brain pathology.

[26]  Satoru Miyano,et al.  Mutational landscape and clonal architecture in grade II and III gliomas , 2015, Nature Genetics.

[27]  E. Shaw,et al.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Huse,et al.  IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma , 2012, Clinical Cancer Research.

[29]  K. Aldape,et al.  Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402 , 2008, Brain pathology.

[30]  P. Pasquini,et al.  Prevalence of hepatitis B infection among hospital personnel in Addis Ababa (Ethiopia) , 1989, European Journal of Epidemiology.

[31]  Y. Kato.  Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas , 2014, Brain Tumor Pathology.